Open access peer-reviewed chapter

Exosomes Decrease In Vitro Infectivity of HIV-1 Preparations: Implication for CD4+T Lymphocyte Depletion In Vivo

By Subra Caroline, Burelout Chantal, Proulx Sophie, Simard Sébastien and Gilbert Caroline

Submitted: November 4th 2010Reviewed: July 6th 2011Published: December 14th 2011

DOI: 10.5772/19846

Downloaded: 1977

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Subra Caroline, Burelout Chantal, Proulx Sophie, Simard Sébastien and Gilbert Caroline (December 14th 2011). Exosomes Decrease In Vitro Infectivity of HIV-1 Preparations: Implication for CD4+T Lymphocyte Depletion In Vivo, Understanding HIV/AIDS Management and Care - Pandemic Approaches in the 21st Century, Fyson Hanania Kasenga, IntechOpen, DOI: 10.5772/19846. Available from:

chapter statistics

1977total chapter downloads

1Crossref citations

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Nikavir in Chemoprevention Regimens of Vertical HIV Transmission

By Elvira Ivanova, Nadezhda Shmagel and Natalia Vorobeva

Related Book

First chapter

Epidemiology and Investigation of Foot‐and‐Mouth Disease (FMD) in the Republic of Korea

By Hachung Yoon, Wooseog Jeong, Jida Choi, Yong Myung Kang and Hong Sik Park

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us